Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2003-01-15
2008-12-02
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S218100, C435S005000
Reexamination Certificate
active
07459160
ABSTRACT:
The invention provides flavivirus vaccines and methods of making and using these vaccines.
REFERENCES:
patent: 6136561 (2000-10-01), Ivy et al.
patent: 6171854 (2001-01-01), Galler et al.
patent: 6184024 (2001-02-01), Lai et al.
patent: 6416763 (2002-07-01), McDonell et al.
patent: 6682883 (2004-01-01), Monath et al.
patent: 6878372 (2005-04-01), Monath et al.
patent: 2003/0044773 (2003-03-01), Kleanthous et al.
patent: 2003/0194801 (2003-10-01), Bonaldo et al.
patent: 2004/0223979 (2004-11-01), Chambers et al.
patent: 2004/0259224 (2004-12-01), Guirakhoo
patent: 2005/0002968 (2005-01-01), Monath et al.
patent: 2005/0053624 (2005-03-01), Arroyo et al.
patent: 2007/0184469 (2007-08-01), Depres et al.
patent: WO 93/06214 (1993-04-01), None
patent: WO 02/072835 (2002-09-01), None
patent: WO 02/102828 (2002-12-01), None
patent: WO 03/063725 (2003-08-01), None
patent: WO 03/101397 (2003-12-01), None
patent: WO 03/103571 (2003-12-01), None
patent: WO 2004/045529 (2004-06-01), None
patent: WO 2005/040390 (2005-05-01), None
patent: WO 2005/049815 (2005-06-01), None
patent: WO 2005/082020 (2005-09-01), None
patent: WO 2006/044857 (2006-04-01), None
patent: WO 2006/116182 (2006-11-01), None
patent: WO 2007/051267 (2007-05-01), None
Theiler, M. “The use of yellow fever virus modified by in vitro cultivation for human immunization” (Rev. Med. Virol. (2000), vol. 10, 3-16).
Caufour, P.S. “Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue tyhpe 2 viruses” (Virus Res. (Nov. 2001) vol. 79, 1-14).
Guirakhoo, F. “Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates” (J. of Virol. (Jun. 2000) vol. 74, No. 12, 5477-5485).
Montath, T.P. “Chimeric Yellow Fever Virus 17D-Japanese Encephalitis virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing inRhesusMonkeys” (J. of Virol. (Feb. 2000) vol. 74, No. 4, 1742).
Van Der Most, R.G. “Chimeric Yellow Fever/Dengue Virus as Candidate Dengue Vaccine: Quantification of the Dengue Virus-Specific CD8 T-Cell Response” (J. of Virol. (2000) vol. 74, No. 17, 8094-8101).
Barret, A.D. “Current Status of Flavivirus Vaccines” Ann. N.Y. Acad. Sci. (Dec. 2001) vol. 951, 262-271).
Monath, Thomas P. The Lancet, Infectious Diseases, Aug. 2001, 1:11-20.
Guirakhoo et al., Journal of Virology, May 2004, 78(9):4761-4775.
Rothman, Alan L. The Journal of Clinical Investigation, Apr. 2004 113(7):946-951.
Chen et al., “Generation and Characterization of Organ-Tropism Mutants of Japanese Encephalitis Virus in Vivo and in Vitro,” Virology 223:79-88, 1996.
Guirakhoo et al., “A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys,” J. Virology 78(18):9998-10008, 2004.
Lee et al., “Changes in the Dengue Virus Major Envelope Protein on Passaging and Their Localization on the Three-Dimensional Structure of the Protein,” Virology 232:281-290, 1997.
Arroyo et al., “Molecular Basis for Attentuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE),” Journal of Virology 75:934-942, 2001.
Bray et al., “Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence,” Journal of Virology 72:1647-1651, 1998.
Chambers et al., “Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties,” Journal of Virology 73:3095-3101, 1999.
dos Santos et al., “Determinants in the Envelope E Protein and Viral RNA Helicase NS3 that Influence the Induction of Apoptosis in Response to Infection with Dengue Type 1 Virus,” Virology 274:292-3089, 2000.
Guirakhoo et al., “Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine,” Journal of Virology 75:7290-7304, 2001.
Hurrelbrink and McMinn, “Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein,” Journal of Virology 75:7692-7702, 2001.
Kanesa-thasan et al., “Safety and Immunogenicity of Attentuated Dengue Virus Vaccines (Aventis Pasteur) in Human Volunteers,” Vaccine 19:3179-3188, 2001.
McMinn, “The Molecular Basis of Virulence of the Encephalitogenic Flaviviruses,” Journal of General Virology 78:2711-2722, 1997.
Monath et al., “Single Mutation In the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Revelence to Development and Safety Testing of Live, Attenuated Vaccines,” Journal of Virology 76:1932-1943, 2002.
Monath, “Molecular Distinctions Between Attentuated (Vaccine) and Virulent Yellow Fever Viruses,” In, Plotkin SA and Orenstein WA (eds). Vaccines, 3rdedition, Saunders (Philadelphia), pp. 815-879, 1999.
Rey et al., “The Envelope Glycoprotein From Tick-Borne Encephalitis Virus at 2Å Resolution,” Nature 375:291-298, 1995.
Wang et al., “Comparison of the Genomes of the Wild-Type French Viscerotropic Strain of Yellow Fever Virus with its Vaccine Derivative French Neurotropic Vaccine,” Journal of General Virology 76:2749-2755, 1995.
Chambers et al., U.S. Appl. No. 09/452,638, filed Dec. 1, 1999.
Chambers et al., U.S. Appl. No. 09/121,587, filed Jul. 23, 1998.
Excerpt from Monath TP. “Yellow fever” In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, Pennsylvania: WB Saunders Company, p. 815-879, 1999.
Vlaycheva et al., “Yellow Fever 17D Virus: Pseudo-Revertant Suppression of Defective Virus Penetration and Spread by Mutuations in Domains II and III of the E protein,” Virology 327:41-49, 2004.
U.S. Appl. No. 08/807,445, filed Feb. 28, 1997, Chambers et al.
U.S. Appl. No. 09/007,664, filed Jan. 15, 1998, Chambers et al.
Allison et al., “Mapping of Functional Elements in the Stem-Anchor Region of Tick-Borne Encephalitis Virus Envelope Protein E,”J. Virology73:5605-5612, 1999.
Allison et al., “Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E,”J. Virology75:4268-4275, 2001.
Arroyo et al., “Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Deparment,”Trends Mol. Med.7:350-354, 2001.
Arroyo et al., “ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy,”J. Virology78:12497-12507, 2004.
Bancroft, “Current Status of Dengue Vaccines and Prospects for the Future,”Puerto Rico Health Sci. J.6(1):23-26, 1987. Abstract only.
Bonaldo et al., “The Yellow Fever 17D Vaccine as a Vector for the Expression of Foreign Proteins: Development of New Live Flavivirus Vaccines,”Mem. Inst. Oswaldo Cruz, Rio de Janeiro95(Suppl. 1):215-223, 2000.
Bonaldo et al., “Surface Expression of an Immunodominant Malaria Protein B Cell Epitope by Yellow Fever Virus,”J. Mol. Biol.315:873-885, 2002.
Bonaldo et al., “Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface,”J. Virology79:8602-8613, 2005.
Bonaldo et al., “Expression of Foreign Protein Epitopes at the Surface or Recombinant Yellow Fever 17D Viruses Based on Three-Dimensional Modeling of Its Envelope Protein,”Cell Biochem. Biophys.44:313-324, 2006.
Bray and Lai, “Construction of Intertypic Chimeric Dengue Viruses by Substitution of Structural Protein Genes,”Proc. Natl. Acad. Sci. U.S.A.88:10342-10346, 1991.
Cardosa, “Dengue Vaccine Design: Issues and Challenges,”British Med. Bull.54(2):395-405, 1998.
Carle et al., “Experiments on the Transmission of an Icterogenic Agent in Yellow Fever Vaccine to Horses and Swi
Arroyo Juan
Guirakhoo Farshad
Monath Thomas P.
Pugachev Konstantin
Acambis Inc.
Chen Stacy B
Clark & Elbing LLP
LandOfFree
Chimeric flaviviruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric flaviviruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric flaviviruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042741